Cryptogenic organizing pneumonia medical therapy

Cryptogenic Organizing Pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cryptogenic organizing pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Electrocardiogram
Ultrasonography/Echocardiography
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cryptogenic organizing pneumonia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cryptogenic organizing pneumonia medical therapy
CDC on Cryptogenic organizing pneumonia medical therapy
Cryptogenic organizing pneumonia medical therapy in the news
Blogs on Cryptogenic organizing pneumonia medical therapy
Directions to Hospitals Treating Cryptogenic organizing pneumonitis
Risk calculators and risk factors for Cryptogenic organizing pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

About two thirds of patients recover with corticosteroid therapy. Prednisolone is often administered in Europe and prednisone in the USA. These two compounds differ by only one functional group and have the same clinical effect. The steroid is initially administered at high doses, typically 50 mg per day tapering down to zero over a 6 month to one year period. If the steroid treatment is halted too quickly the disease may return.